Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 2074-2084, 2005. First published September 15, 2005; 10.1373/clinchem.2005.050831
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.050831v1
51/11/2074    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dervieux, T.
Right arrow Articles by Seidman, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dervieux, T.
Right arrow Articles by Seidman, E.
Related Collections
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2005;51:2074-2084.)
© 2005 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Liquid Chromatography–Tandem Mass Spectrometry Analysis of Erythrocyte Thiopurine Nucleotides and Effect of Thiopurine Methyltransferase Gene Variants on These Metabolites in Patients Receiving Azathioprine/6-Mercaptopurine Therapy

Thierry Dervieux1,a, Gary Meyer1, Robert Barham1, Mariko Matsutani1, Mary Barry1, Roselyne Boulieu2, Bruce Neri1 and Ernest Seidman3

1 Prometheus Laboratories, San Diego, CA.
2 Department of Clinical Pharmacy, Claude Bernard University, Lyon, France.
3 Division of Gastroenterology, Research Institute of the McGill University Health Sciences Center, Montreal, Quebec, Canada.

aAddress correspondence to this author at: Prometheus Laboratories, 5739 Pacific Center Blvd, San Diego, CA 92121. Fax 858-332-3349; e-mail tdervieux{at}prometheuslabs.com.

Background: Polymorphic thiopurine S-methyltransferase (TPMT) is a major determinant of thiopurine toxicity.

Methods: We extracted 6-thioguanine nucleotides (6-TGNs) and 6-methylmercaptopurine nucleotides (6-MMPNs) from erythrocytes with perchloric acid and converted them to 6-thioguanine (6-TG) and a 6-methylmercaptopurine (6-MMP) derivative during a 60-min acid hydrolysis step. The liquid chromatography system consisted of a C18 column with an ammonium acetate–formic acid–acetonitrile buffer. 8-Bromoadenine was the internal standard. Analytes were measured with positive ionization and multiple reaction monitoring mode. With PCR–restriction fragment length polymorphism analysis and TaqMan allelic discrimination, common TPMT alleles (*1, *2, *3A, *3B, *3C) were determined in 31 792 individuals. We used perchloric acid extraction, acid hydrolysis, and HPLC with ultraviolet detection to measure erythrocyte 6-TG and 6-MMP nucleotide concentrations in 6189 patients with inflammatory bowel disease receiving azathioprine/6-mercaptopurine therapy.

Results: Intra- and interday imprecision were <10% at low and high analyte concentrations. The conversion of 6-TG and 6-MMP nucleoside mono-, di-, and triphosphates was complete after hydrolysis. Allelic frequency for TPMT variant alleles ranged from 0.0063% (*3B) to 3.61% (*3A). Compared with wild types, TPMT heterozygotes had an 8.3-fold higher risk for 6-TGNs >450 pmol/8 x 108 erythrocytes (concentration associated with increased risk for leukopenia), but an 8.2-fold lower risk for 6-MMPNs >5700 pmol/8 x 108 erythrocytes (concentration associated with increased risk for hepatotoxicity).

Conclusions: The liquid chromatography–tandem mass spectrometry method can be applied to the routine monitoring of thiopurine therapy. The association between TPMT genotype and metabolite concentrations illustrates the utility of pharmacogenetics in the management of patients undergoing treatment with thiopurines.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Gen. Virol.Home page
S. Hoover and R. Striker
Thiopurines inhibit bovine viral diarrhea virus production in a thiopurine methyltransferase-dependent manner
J. Gen. Virol., April 1, 2008; 89(4): 1000 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J A Duley, A M Marinaki, M Arenas, T H J Florin, M van Dieren, A J van Vuuren, E J Kuipers, B E Hansen, J G Kusters, E E S Nieuwenhuis, et al.
Do ITPA and TPMT genotypes predict the development of side effects to AZA? * Authors' reply
Gut, July 1, 2006; 55(7): 1048 - 1049.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.